Exact Sciences Corporation (EXAS)

Market Cap	7.97B
Revenue (ttm)	2.53B
Net Income (ttm)	-240.23M
Shares Out	184.53M
EPS (ttm)	-1.32
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,794,533
Open	42.37
Previous Close	42.43
Day's Range	41.89 - 43.25
52-Week Range	40.62 - 100.77
Beta	1.26
Analysts	Strong Buy
Price Target	88.33 (+104.61%)
Earnings Date	Jul 30, 2024

About EXAS

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Co...

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 1995
• Employees: 6,600
• Stock Exchange: NASDAQ
• Ticker Symbol: EXAS

Financial Performance

In 2023, Exact Sciences's revenue was $2.50 billion, an increase of 19.93% compared to the previous year's $2.08 billion. Losses were -$204.15 million, -67.26% less than in 2022.

Analyst Forecast

According to 13 analysts, the average rating for EXAS stock is "Strong Buy." The 12-month stock price forecast is $88.33, which is an increase of 104.61% from the latest price.

Price Target

$88.33

(104.61% upside)

Analyst Consensus: Strong Buy